search

Qilu King-Phar successfully passes the US FDA inspection with no 483 observations

ABOUT US

图片名称

Qilu King-Phar successfully passes the US FDA inspection with no 483 observations


Release time:

2017-04-19

March 23, Qilu Pharmaceutical announces that its subsidiary King-Phar Pharmaceutical successfully has passed the US FDA inspection with no 483 observations for the third time.

Many aspects including material management, production management, quality management, laboratory management and packaging system are involved in this inspection and the performance of cGMP is highly praised by the auditor.

‘One millionth of the manufacturer is 100% of the patients’.  Qilu Pharmaceutical has always been attaching great importance to the product quality and the quality system is strictly constructed to be geared to international standards. With the aim of exploring the international high-end markets, Qilu Pharmaceutical will continue adhering to the normalization for high standard of the production and quality management in the future,

齐鲁制药有限公司
齐鲁制药有限公司
齐鲁制药有限公司

Tel: +86-531-83127705831277048312770683127711

Address: 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China

Email:export@qilu-pharma.com


监督举报

亲爱的合作伙伴:

欢迎举报以下行为!

索贿、暗箱操纵招标、内定中标单位、员工或亲属参与公司业务往来牟取私利、偷工减料、以次充好、故意刁难供应商等行为。

举报电话:0531-83126898/55820713/83126871

举报邮箱:qljc@qilu-pharma.com

收信地址:山东省济南市历城区旅游路8888号

齐鲁制药集团审计监察部

采购平台技术专线